(English) European Patent Office Grants Cellect Biotechnology Pivotal Patent for Stem Cells Activation

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ — Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that it has significantly strengthened its Intellectual Property (IP) portfolio as European Patent Application No. 14851547.1 has been granted. The patent will be set to expire in October 7, 2034, subject to patent term adjustment or extension. 

«This is a pivotal…